OKI-179

OnKure, Inc. · Phase 1 active Small molecule

At a glance

Generic name	OKI-179
Sponsor	OnKure, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) (PHASE1, PHASE2)
A Study of OKI-179 in Patients With Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OKI-179 CI brief — competitive landscape report
OKI-179 updates RSS · CI watch RSS
OnKure, Inc. portfolio CI